| Literature DB >> 34035663 |
Carmen Charlton1,2,3, Jamil Kanji1,2,4, Vanessa Tran5,6, Julianne Kus5,6, Jonathan Gubbay5,6, Carla Osiowy7, Jason Robinson8, Inna Sekirov9, Michael Drebot7, Todd Hatchette10, Derek Stein11,12, Nadia El-Gabalawy7, Amanda Lang13, Lei Jiao10, Paul Levett11, Heidi Wood7, Christian Therrien14, L Robbin Lindsay7, Muhammad Morshed9, Jessica Forbes6, Antonia Dibernardo7.
Abstract
The landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic testing is rapidly evolving. While serology testing has limited diagnostic capacity for acute infection, its role in providing population-based information on positivity rates and informing evidence-based decision making for public health recommendations is increasing. With the global availability of vaccines, there is increasing pressure on clinical laboratories to provide antibody screening and result interpretation for vaccinated and non-vaccinated individuals. Here we present the most up-to-date data on SARS-CoV-2 antibody timelines, including the longevity of antibodies, and the production and detection of neutralizing antibodies. Additionally, we provide practical guidance for clinical microbiology laboratories to both verify commercial serology assays and choose appropriate testing algorithms for their local populations.Entities:
Keywords: COVID-19; SARS-CoV-2; serological testing; serology algorithms
Year: 2021 PMID: 34035663 PMCID: PMC8127682 DOI: 10.14745/ccdr.v47i04a01
Source DB: PubMed Journal: Can Commun Dis Rep ISSN: 1188-4169